For UGT1A1 c.1135del (p.Tyr379fs), liver-directed gene replacement remains the clearest current platform fit

For UGT1A1 c.1135del (p.Tyr379fs), a frameshift variant expected to abolish normal UGT1A1 activity, liver-directed gene replacement remains the clearest current platform fit because it bypasses the disrupted endogenous allele and restores functional enzyme expression in hepatocytes. The key translational uncertainty remains durable bilirubin control, not whether this allele fits the platform.

ClinVar classifies c.1135del (p.Tyr379fs) as likely pathogenic. Optimized AAV-UGT1A1 programs have shown durable bilirubin correction in preclinical Crigler-Najjar models, providing strong mechanistic support for gene addition in severe UGT1A1 deficiency (PMID:27722180; PMID:29448836). In the clinic, GNT0003 has produced meaningful bilirubin reduction and major decreases in phototherapy dependence, making liver-directed AAV therapy the most advanced gene-therapy route currently under active evaluation for Crigler-Najjar syndrome (PMID:37585628; NCT:NCT03466463). For a truncating frameshift allele like p.Tyr379fs, this disease-level logic is more mature than any allele-specific correction concept.

The evidence is disease-level rather than variant-specific. Pediatric hepatocyte turnover, immune barriers, uncertain redosing feasibility, and comparison with liver transplantation remain the dominant translational constraints. This post should therefore be read as a strong platform-fit interpretation for a severe UGT1A1 loss-of-function allele, not as proof of unique responsiveness for p.Tyr379fs.